細(xì)胞名稱

4T1小鼠乳腺癌細(xì)胞

描述

4T1 是從410.4瘤株中未經(jīng)誘變篩得的6-硫鳥嘌噙抗性細(xì)胞株。 當(dāng)注射到BALB/c 小鼠中時，4T1自發(fā)產(chǎn)生高轉(zhuǎn)移腫瘤，可轉(zhuǎn)移到肺，肝，淋巴結(jié)和大腦，同時在注射部位形成始發(fā)灶。 誘導(dǎo)轉(zhuǎn)移時不需要摘除始發(fā)灶。 4T1細(xì)胞在BALB/c小鼠中的生長與轉(zhuǎn)移特性與人體中的乳腺癌十分相近。這種腫瘤是人VI期乳腺癌的動物模型。 4T1-誘導(dǎo)的腫瘤在手術(shù)后及未手術(shù)情況下轉(zhuǎn)移的動力學(xué)相近，可以用作手術(shù)后及未手術(shù)模型。 跟其他腫瘤模型相比，由于4T1的抗6-硫鳥嘌噙特性，微小的轉(zhuǎn)移細(xì)胞團(tuán)(少到僅僅1個)也可以在許多遠(yuǎn)端器官中檢測到。 沒必要數(shù)淋巴結(jié)或稱重器官。

動物種別

小鼠

性別

***

組織來源

乳腺癌

形態(tài)

上皮細(xì)胞

培養(yǎng)基和添加劑

RPMI-1640(GIBCO,貨號31800022, 添加NaHCO3 1.5g/L, glucose 2.5g/L, Sodium Pyruvate 0.11g/L)，90%；優(yōu)質(zhì)胎牛血清，10%。 氣相：空氣，95%；二氧化碳，5%。 溫度：37攝氏度。

供應(yīng)限制

REFERENCE

Pulaski BA , et al. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. Cancer Immunol. Immunother. 49: 34-45, 2000. PubMed: 10782864 Pulaski BA , Ostrand-Rosenberg S . Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 58: 1486-1493, 1998. PubMed: 9537252 Pulaski BA , et al. Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res. 60: 2710-2715, 2000. PubMed: 10825145 Aslakson CJ , Miller FR . Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52: 1399-1405, 1992. PubMed: 1540948